Drug intelligence / Profile preview

JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736

Development stage: Discontinued
Lead developer: OMJ Pharmaceuticals
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Subcutaneous, Intramuscular

Overview

JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736 is a multi-modal combination therapy regimen developed by Janssen for the treatment of chronic hepatitis B virus (HBV) infection. The regimen is designed to achieve a functional cure by targeting multiple stages of the HBV lifecycle and stimulating the host immune response. It consists of JNJ-73763989, an RNA interference (RNAi) therapeutic that silences all HBV RNA transcripts; JNJ-64300535, a capsid assembly modulator (CAM) that interferes with viral nucleocapsid formation; standard-of-care nucleos(t)ide analogs (NAs) that inhibit viral reverse transcription; and JNJ-64301736, a therapeutic DNA vaccine delivered via Ichor Medical Systems' TriGrid electroporation technology to induce T-cell responses against HBV antigens. In 2023, Janssen announced the discontinuation of its hepatitis B research and development portfolio, including this combination program.

Other names: JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs-Janssen (collaboration)-HBV antigens-DNA Vaccine-HBVREEF-D regimen

Targets

HBV antigens (Hepatitis B virus antigens)HBV RNA (Hepatitis B virus RNA)HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736.

Explore the full profile